Hosted on MSN14h
Keymed’s Stapokibart approved by NMPA for seasonal allergic rhinitis
China's National Medical Products Administration (NMPA) has approved Keymed Biosciences’ supplemental new drug application ...
Keymed Biosciences Inc.: Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental ...
ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions
ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions.
thecardiologyadvisor.com7d
Nasal Spray Formulation of Bumetanide Under FDA Review
The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
WebMD18d
Decongestants and Antihistamines for Colds
The common cold usually lasts 7-10 days. Decongestants are available as pills, liquids, nasal sprays, and nasal drops. How to find a good decongestant Two common decongestants are ...
Metro18d
Fans injured after pepper spray attack at chart-topping rapper’s show
JPEGMafia had to cut his show short due to a pepper spray incident (Picture: Sergione Infuso/Corbis via Getty Images) Six people were hospitalized following a pepper spray incident at JPEGMafia ...
healthday19d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...
U.S. News & World Report20d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...
Newsweek20d
FDA Approves Nasal Spray for Depression
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...
New York Post20d
J&J’s ketamine-derived nasal spray approved by FDA to treat depression
The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...
CNN20d
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...
Gizmodo20d
Ketamine-Derived Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...